Newport Beach, Calif.-based Hoag is one of three sites enrolling patients in a post-market study collecting clinical outcomes for a new mitral valve replacement option.
The study will follow patients who receive the new Mitris Resilia valve developed by Edwards Lifesciences, according to an April 17 press release.
The valve has already been approved by the FDA, and Hoag has performed more than a dozen mitral valve replacements in the last eight months.
Hoag's study investigators include surgeons Anthony Caffarelli, MD, Asad Shah, MD, and Timothy Lee, MD.